ST诺泰涨0.32%，成交额1.15亿元，近3日主力净流入7063.24万

Core Viewpoint - ST诺泰 is experiencing a positive market response with a slight increase in stock price and significant trading volume, indicating investor interest in the company's growth potential and product pipeline [1]. Group 1: Business Overview - The company specializes in custom products, primarily through its CDMO (Contract Development and Manufacturing Organization) business, which emphasizes the integration of high-tech process development and large-scale production capabilities [2]. - ST诺泰's main revenue sources include raw materials and intermediates (64.98%), CDMO/CMO services (25.48%), formulations (7.00%), technical service fees (2.49%), and other income (0.06%) [8]. Group 2: Product Pipeline - The company has developed Thymosin Alpha 1 for the treatment of chronic hepatitis B [3]. - ST诺泰's GLP-1 receptor agonist, SPN0103-009, for diabetes and weight loss has received clinical trial approval [3]. - The company has also obtained approval for Oseltamivir Phosphate capsules, an antiviral medication for treating and preventing influenza [3]. Group 3: Financial Performance - For the period from January to September 2025, ST诺泰 reported revenue of 1.527 billion yuan, a year-on-year increase of 21.95%, and a net profit attributable to shareholders of 445 million yuan, up 26.92% year-on-year [8]. - The company's overseas revenue accounted for 63.12% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Group 4: Market Activity - The stock has seen a net inflow of 7.2827 million yuan from major investors today, with a total industry net inflow of 765 million yuan over the past three days [5][6]. - The average trading cost of the stock is 41.73 yuan, with the current price near a support level of 40.22 yuan, indicating potential for short-term trading opportunities [7].